Immunotherapy News and Research

Latest Immunotherapy News and Research

DANTE trial reveals promising outcomes for shortened immunotherapy in advanced melanoma

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.

5 Jun 2025

Key proteins and pathways drive the success of CAR-T cell therapy

A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways involved in the efficacy of immunotherapy based on CAR-T cells (lymphocytes modified in the laboratory to fight cancer).

4 Jun 2025

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

2 Jun 2025

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor destruction in aggressive cancer models.

2 Jun 2025

Genome doubling identified as common event in metastatic cancer evolution

When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity.

2 Jun 2025

New combination treatment offers hope for immune checkpoint blockade resistant skin cancers

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.

2 Jun 2025

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

1 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

31 May 2025

Pitt professor wins NSF CAREER Award for AI-driven immunotherapy research

The University of Pittsburgh's Natasa Miskov-Zivanov, assistant professor of electrical and computer engineering, has received a prestigious Faculty Early Career Development (CAREER) Award of $581,503 from the National Science Foundation (NSF) for her project titled "Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design."

30 May 2025

TRR 417 initiative aims to unlock new treatments for colorectal cancer

In the realm of colorectal cancer treatments beyond surgery and radiation, one key question gained prominence in recent years: Is the tumor's DNA repair system defective, making it "microsatellite unstable"? Around 15 to 20 percent of all tumors have this trait, making them likely candidates for successful immunotherapy.

30 May 2025

TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.

30 May 2025

Immunotherapy News and Research

Latest Immunotherapy News and Research

DANTE trial reveals promising outcomes for shortened immunotherapy in advanced melanoma

Key proteins and pathways drive the success of CAR-T cell therapy

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

Navigating the dual role of B cells in tumor immunity

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Engineered viruses and gene therapy halt tumor growth and extend survival in mice

Genome doubling identified as common event in metastatic cancer evolution

New combination treatment offers hope for immune checkpoint blockade resistant skin cancers

Adding immunotherapy to chemotherapy after surgery improves survival in colon cancer

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

Combination treatment extends progression-free survival in advanced skin cancer

Universal CAR T cell therapy shows promise for aggressive T cell cancers

Pitt professor wins NSF CAREER Award for AI-driven immunotherapy research

TRR 417 initiative aims to unlock new treatments for colorectal cancer

TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer

New insights into decades-old bladder cancer treatment offers clues for immunotherapy

Early allergen introduction reduces childhood food allergy risk

New four drug combination sets new standard in myeloma care

BCG immunotherapy reprograms bone marrow to boost cancer defense

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in